{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:54:52Z","timestamp":1793040892872,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>Genetic activation of the insulin signal-transducing kinase <jats:italic>AKT2<\/jats:italic> causes syndromic hypoketotic hypoglycaemia without elevated insulin. Mosaic activating mutations in class 1A phospatidylinositol-3-kinase (PI3K), upstream from AKT2 in insulin signalling, are known to cause segmental overgrowth, but the metabolic consequences have not been systematically reported. We assess the metabolic phenotype of 22 patients with mosaic activating mutations affecting PI3K, thereby providing new insight into the metabolic function of this complex node in insulin signal transduction.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Three patients with megalencephaly, diffuse asymmetric overgrowth, hypoketotic, hypoinsulinaemic hypoglycaemia and no <jats:italic>AKT2<\/jats:italic> mutation underwent further genetic, clinical and metabolic investigation. Signalling in dermal fibroblasts from one patient and efficacy of the mTOR inhibitor Sirolimus on pathway activation were examined. Finally, the metabolic profile of a cohort of 19 further patients with mosaic activating mutations in PI3K was assessed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In the first three patients, mosaic mutations in <jats:italic>PIK3CA<\/jats:italic> (p.Gly118Asp or p.Glu726Lys) or <jats:italic>PIK3R2<\/jats:italic> (p.Gly373Arg) were found. In different tissue samples available from one patient, the <jats:italic>PIK3CA<\/jats:italic> p.Glu726Lys mutation was present at burdens from 24% to 42%, with the highest level in the liver. Dermal fibroblasts showed increased basal AKT phosphorylation which was potently suppressed by Sirolimus. Nineteen further patients with mosaic mutations in <jats:italic>PIK3CA<\/jats:italic> had neither clinical nor biochemical evidence of hypoglycaemia.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Mosaic mutations activating class 1A PI3K cause severe non-ketotic hypoglycaemia in a subset of patients, with the metabolic phenotype presumably related to the extent of mosaicism within the liver. mTOR or PI3K inhibitors offer the prospect for future therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1530\/eje-17-0132","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:25:27Z","timestamp":1496276727000},"page":"175-186","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":36,"title":["Hypoinsulinaemic, hypoketotic hypoglycaemia due to mosaic genetic activation of PI3-kinase"],"prefix":"10.1093","volume":"177","author":[{"given":"Sarah M","family":"Leiter","sequence":"first","affiliation":[{"name":"1Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK"},{"name":"2The National Institute for Health Research, Cambridge Biomedical Research Centre, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria E R","family":"Parker","sequence":"additional","affiliation":[{"name":"1Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK"},{"name":"2The National Institute for Health Research, Cambridge Biomedical Research Centre, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Welters","sequence":"additional","affiliation":[{"name":"3Department of General Paediatrics, Neonatology and Paediatric Cardiology, University Children\u2019s Hospital, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Knox","sequence":"additional","affiliation":[{"name":"1Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK"},{"name":"2The National Institute for Health Research, Cambridge Biomedical Research Centre, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Rocha","sequence":"additional","affiliation":[{"name":"1Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK"},{"name":"2The National Institute for Health Research, Cambridge Biomedical Research Centre, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Clark","sequence":"additional","affiliation":[{"name":"4Department of Molecular Genetics, Addenbrooke\u2019s Hospital, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicity","family":"Payne","sequence":"additional","affiliation":[{"name":"5Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Lotta","sequence":"additional","affiliation":[{"name":"6MRC Epidemiology Unit, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Harris","sequence":"additional","affiliation":[{"name":"1Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK"},{"name":"2The National Institute for Health Research, Cambridge Biomedical Research Centre, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Guerrero-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"7Departments of Paediatric Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Gonz\u00e1lez-Casado","sequence":"additional","affiliation":[{"name":"7Departments of Paediatric Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixto","family":"Garc\u00eda-Mi\u00f1aur","sequence":"additional","affiliation":[{"name":"8Departments of Clinical and Molecular Genetics, La Paz Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Gordo","sequence":"additional","affiliation":[{"name":"8Departments of Clinical and Molecular Genetics, La Paz Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Wareham","sequence":"additional","affiliation":[{"name":"6MRC Epidemiology Unit, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Mart\u00ednez-Glez","sequence":"additional","affiliation":[{"name":"8Departments of Clinical and Molecular Genetics, La Paz Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Allison","sequence":"additional","affiliation":[{"name":"9Departments of Hepatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"O\u2019Rahilly","sequence":"additional","affiliation":[{"name":"1Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK"},{"name":"2The National Institute for Health Research, Cambridge Biomedical Research Centre, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Barroso","sequence":"additional","affiliation":[{"name":"1Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK"},{"name":"2The National Institute for Health Research, Cambridge Biomedical Research Centre, Cambridge, UK"},{"name":"5Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Meissner","sequence":"additional","affiliation":[{"name":"3Department of General Paediatrics, Neonatology and Paediatric Cardiology, University Children\u2019s Hospital, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Davies","sequence":"additional","affiliation":[{"name":"10Departments of Histopathology, Addenbrooke\u2019s Hospital, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Hussain","sequence":"additional","affiliation":[{"name":"11Institute of Child Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Temple","sequence":"additional","affiliation":[{"name":"12Department of Clinical Genetics, University Hospital Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Coral","family":"Barreda-Bonis","sequence":"additional","affiliation":[{"name":"7Departments of Paediatric Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kummer","sequence":"additional","affiliation":[{"name":"3Department of General Paediatrics, Neonatology and Paediatric Cardiology, University Children\u2019s Hospital, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K","family":"Semple","sequence":"additional","affiliation":[{"name":"1Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK"},{"name":"2The National Institute for Health Research, Cambridge Biomedical Research Centre, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"ref111","first-page":"21","article-title":"Phosphoinositide 3-kinase in Health and Disease","volume-title":"In Current Topics in Microbiology and Immunology,","volume":"347","year":"2011"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"7078","DOI":"10.1038\/ncomms8078","article-title":"Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo","volume":"6","year":"2015","journal-title":"Nature Communications"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"12260","DOI":"10.1021\/bi801683k","article-title":"Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain","volume":"47","year":"2008","journal-title":"Biochemistry"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ymgme.2014.11.018","article-title":"Germline activating AKT3 mutation associated with megalencephaly, polymicrogyria, epilepsy and hypoglycemia","volume":"114","year":"2015","journal-title":"Molecular Genetics and Metabolism"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.ijo.0802929","article-title":"Lower-body fat mass as an independent marker of insulin sensitivity \u2013 the role of adiponectin","volume":"29","year":"2005","journal-title":"International Journal of Obesity (2005)"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2006.04.005","article-title":"Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda\/zeta","volume":"3","year":"2006","journal-title":"Cell Metabolism"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.siny.2005.03.001","article-title":"Congenital hyperinsulinism","volume":"10","year":"2005","journal-title":"Seminars in Fetal and Neonatal Medicine"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/13813455.2010.539236","article-title":"Promiscuous affairs of PKB\/AKT isoforms in metabolism","volume":"117","year":"2011","journal-title":"Archives of Physiology and Biochemistry"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/SAP.0b013e318062abc1","article-title":"Klippel-Trenaunay syndrome: diagnostic criteria and hypothesis on etiology","volume":"60","year":"2008","journal-title":"Annals of Plastic Surgery"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/ng.2331","article-title":"De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes \u2013 supplementary information","volume":"44","year":"2012","journal-title":"Nature Genetics"},{"key":"ref51","first-page":"533","article-title":"Pathophysiology of fatty acid oxidation disorders","volume":"33","year":"2009","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ajmg.a.36836","article-title":"PIK3CA-related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluation","volume":"167","year":"2015","journal-title":"American Journal of Medical Genetics Part A"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.05.006","article-title":"Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome","volume":"90","year":"2012","journal-title":"American Journal of Human Genetics"},{"key":"ref271","article-title":"Phenotypic heterogeneity in PIK3CA-Related Overgrowth Spectrum (PROS)","volume":"175","year":"2016","journal-title":"British Journal of Dermatology"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/nature14962","article-title":"The UK10K project identifies rare variants in health and disease \u2013 supplementary information","volume":"526","year":"2015","journal-title":"Nature"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","year":"2004","journal-title":"Science"},{"key":"ref71","first-page":"1","article-title":"An activating mutation of AKT2 and human hypoglycemia \u2013 supporting oline materials","volume":"334","year":"2011","journal-title":"Science"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/hep.20130","article-title":"Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers","volume":"39","year":"2004","journal-title":"Hepatology"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1172\/JCI115345","article-title":"Effects of body fat distribution on regional lipolysis in obesity","volume":"88","year":"1991","journal-title":"Journal of Clinical Investigation"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1310967","article-title":"Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia","volume":"370","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"ref211","first-page":"122","article-title":"Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP","volume":"163C","year":"2013","journal-title":"American Journal of Medical Genetics: Part C, Seminars in Medical Genetics"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2265.2010.03810.x","article-title":"What is the best management strategy for patients with severe insulin resistance?","volume":"73","year":"2010","journal-title":"Clinical Endocrinology"},{"key":"ref311","article-title":"Constitutive activation of AKT2 in humans leads to hypoglycemia without fatty liver or metabolic dyslipidemia","year":"2017","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1002\/ajmg.a.32023","volume":"143A","year":"2007","journal-title":"American Journal of Medical Genetics Part A"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/MED.0b013e328334f061","article-title":"Neonatal hypoglycemia","volume":"17","year":"2010","journal-title":"Current Opinion in Endocrinology, Diabetes and Obesity"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jmg.2008.064337","article-title":"The genetic basis of congenital hyperinsulinism","volume":"46","year":"2009","journal-title":"Journal of Medical Genetics"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ajhg.2015.11.011","article-title":"Somatic activating PIK3CA mutations cause venous malformation","volume":"97","year":"2015","journal-title":"American Journal of Human Genetics"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jpeds.2015.09.045","article-title":"Biomarkers of insulin for the diagnosis of hyperinsulinemic hypoglycemia in infants and children","volume":"168","year":"2016","journal-title":"Journal of Pediatrics"},{"key":"ref171","first-page":"1","article-title":"PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution","volume":"1","year":"2016","journal-title":"JCI Insight"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","year":"2006","journal-title":"Molecular Cell"},{"key":"ref291","article-title":"Direct hepatocyte insulin signaling is required for lipogenesis but is dispensable for the suppression of glucose production","volume":"23","year":"2016","journal-title":"Cell Metabolism"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/ajmg.a.36454","article-title":"Segmental overgrowth syndrome due to an activating PIK3CA mutation identified in affected muscle tissue by exome sequencing","volume":"164","year":"2014","journal-title":"American Journal of Medical Genetics Part A"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1023\/A:1021831621210","article-title":"Glycogen storage diseases","volume":"4","year":"2003","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0898-6568(99)00086-8","article-title":"Structure and function of phosphatidylinositol-3,4 kinase","volume":"12","year":"2000","journal-title":"Cellular Signalling"},{"key":"ref261","first-page":"2011","article-title":"An activating mutation of AKT2 and human hypoglycemia","volume":"334","year":"2011","journal-title":"Science"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/ng.2332","article-title":"Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA","volume":"44","year":"2012","journal-title":"Nature Genetics"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/177\/2\/EJE-17-0132.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1530\/EJE-17-0132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:10:40Z","timestamp":1676391040000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/177\/2\/175\/6655248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":36,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/eje-17-0132","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}